Clinical Trial Update: Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating once-daily raltegravir (800 mg) with unboosted atazanavir (400 mg) in HIV-1 infected patients; completed study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Raltegravir (raltegravir)
• Unboosted atazanavir (atazanavir)

Snippet

Sponsor: Germans Trias i Pujol Hospital | Conditions: HIV Infections | Phase 4 | Status: COMPLETED